BioVaxys Technology Corp. announced that it has received a Notice of Allowance from the United States Patent and Tradark Office for a Patent for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV Inc, this Patent was recently allowed in Japan and is currently pending in the European Union.

DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response. The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone?

Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX? formulated B-cell epitope is designed to be delivered in single dose as low as 50µL to 90 µL. An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen.

It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection. BioVaxys also is pleased to announced it has entered the national phase in the United States, Canada, European Union, Japan, and Australia with its patent application for DPX?-survivin/MAGE A9 ("DPX?

SurMAGE"), a DPX? formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. The survivins and MAGE-A9 are frequently over-expressed in various human cancers including bladder, lung and kidney, and correlate with a resistance to chemotherapy and aggressiveness of tumors, and both are recognized as important targets for cancer vaccines and therapeutics.

DPX? SurMAGE" recently completed a successful Phase I clinical study in Canada with bladder cancer patients conducted at CHU de Québec-Université Laval, and induced a robust peptide-specific T cell response. Kovan further added that "BioVaxys and the Phase 1 clinical study investigators see the potential with further evaluation of DPX?

SurMAGE, and are particularly excited by the proven ability of DPX? to package multiple different antigens.